Haadi Pharma Ltd - Accounts

Haadi Pharma Ltd
Contents Page
For the year ended 31 March 2026

Company information	1
Director's report	2
Accountants' report	3
Statement of financial position	4
Notes to the financial statements	5
Statement of changes in equity	6

Haadi Pharma Ltd
Company Information
For the year ended 31 March 2026

Director	Abdul Qadeer Sajid
Registered Number	10702145
Registered Office	19 Cowdray Court Newcastle Upon Tyne Tyne & Wear NE3 2TZ
Accountants	Acumen Accounting 364 West Road Newcastle Upon Tyne NE4 9JY

1

Haadi Pharma Ltd
Director's Report
For the year ended 31 March 2026

Director's report and financial statements

The director presents his/her/their annual report and the financial statements for the year ended 31 March 2026.

Principal activities

Principal activity of the company during the financial year end 31 March 2026 was of Other human health activities.

Director

The director who served the company throughout the year was as follows:

Abdul Qadeer Sajid

Statement of director's responsibilities

The director is responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations and in accordance with United Kingdom Generally Accepted Accounting Practice.
Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that period.

In preparing these financial statements, the director is required to :

select suitable accounting policies and then apply them consistently
make judgements and accounting estimates that are reasonable and prudent
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements and
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. The director is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The director is responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom, governing the preparation and dissemination of financial statements, may differ from legislation in other jurisdictions

On behalf of the board.

----------------------------------
Abdul Qadeer Sajid
Director

Date approved: 28 April 2026

2

Haadi Pharma Ltd Accountants' Report For the year ended 31 March 2026
Accountant’s report You consider that the company is exempt from an audit for the year ended 31 March 2026 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year. In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us. We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts. Acumen Accounting 31 March 2026 .................................................... Acumen Accounting 364 West Road Newcastle Upon Tyne NE4 9JY 28 April 2026 3

Haadi Pharma Ltd
Accountants' Report
For the year ended 31 March 2026

Accountant’s report
You consider that the company is exempt from an audit for the year ended 31 March 2026 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year.
In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us.
We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts.
Acumen Accounting
31 March 2026

....................................................
Acumen Accounting
364 West Road
Newcastle Upon Tyne
NE4 9JY
28 April 2026

3

Haadi Pharma Ltd
Statement of Financial Position
As at 31 March 2026

	Notes	2026 £	2025 £
Current assets
Debtors: amounts falling due within one year	3	0	1,500
Cash at bank and in hand		16,009	18,125
		16,009	19,625
Creditors: amount falling due within one year	4	(19,621)	(9,249)
Net current assets		(3,612)	10,376

Total assets less current liabilities		(3,612)	10,376
Creditors: amount falling due after more than one year	5	0	(12,636)
Net assets		(3,612)	(2,260)

Capital and reserves
Called up share capital	6	100	100
Profit and loss account		(3,712)	(2,360)
Shareholders' funds		(3,612)	(2,260)

For the year ended 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The financial statements were approved by the director on 28 April 2026 and were signed by:

-------------------------------
Abdul Qadeer Sajid
Director

4

Haadi Pharma Ltd
Statement of Changes in Equity
For the year ended 31 March 2026

	Equity share capital	Retained Earnings	Total
	£	£	£
At 01 April 2024	100	1,621	1,721
Profit for the year		(3,981)	(3,981)
Total comprehensive income for the year	-	(3,981)	(3,981)
Total investments by and distributions to owners	-	-	-
At 31 March 2025	100	(2,360)	(2,260)
At 01 April 2025	100	(2,360)	(2,260)
Profit for the year		(1,352)	(1,352)
Total comprehensive income for the year	-	(1,352)	(1,352)
Total investments by and distributions to owners	-	-	-
At 31 March 2026	100	(3,712)	(3,612)

5

Haadi Pharma Ltd
Notes to the Financial Statements
For the year ended 31 March 2026

General Information

Haadi Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 10702145, registration address 19 Cowdray Court, Newcastle Upon Tyne, Tyne & Wear, NE3 2TZ.

The presentation currency is £ sterling.

1.

Accounting policies

Significant accounting policies

Statement of compliance

These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

Basis of preparation

The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.

The financial statements are prepared in sterling which is the functional currency of the company.

Turnover

Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.

Taxation

Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted

Provisions

Provisions are recognised when the company has a present obligation as a result of a past event which it is more probable than not will result in an outflow of economic benefits that can be reasonably estimated.

2.	Average number of employees Average number of employees during the year was 1 (2025 : 1).

3.

Debtors: amounts falling due within one year

	2026 £		2025 £
Other Debtors	0		1,500
	0		1,500

4.

Creditors: amount falling due within one year

	2026 £	2025 £
Corporation Tax	250	250
Accrued Expenses	1,800	1,800
Other Creditors	0	(1)
Directors' Current Accounts	17,571	7,200
	19,621	9,249

5.

Creditors: amount falling due after more than one year

	2026 £		2025 £
Bank Loans & Overdrafts	0		12,636
	0		12,636

6.

Share Capital

Allotted, called up and fully paid	2026 £		2025 £
1 Class A share of £1.00 each	1		1
	1		1

6

Registered Number: 10702145
England and Wales
HAADI PHARMA LTD

Unaudited Financial Statements

Period of accounts Start date: 01 April 2025 End date: 31 March 2026